CN1118990A - 治疗或预防脑血管疾病药物 - Google Patents

治疗或预防脑血管疾病药物 Download PDF

Info

Publication number
CN1118990A
CN1118990A CN94191403A CN94191403A CN1118990A CN 1118990 A CN1118990 A CN 1118990A CN 94191403 A CN94191403 A CN 94191403A CN 94191403 A CN94191403 A CN 94191403A CN 1118990 A CN1118990 A CN 1118990A
Authority
CN
China
Prior art keywords
hydrogen
alkyl group
low
chemical compound
rudimentary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94191403A
Other languages
English (en)
Chinese (zh)
Inventor
胜田清贵
高松宏幸
上田佳子
中西一
吉田启造
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939304701A external-priority patent/GB9304701D0/en
Priority claimed from GB939320882A external-priority patent/GB9320882D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1118990A publication Critical patent/CN1118990A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN94191403A 1993-03-08 1994-02-16 治疗或预防脑血管疾病药物 Pending CN1118990A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9304701.7 1993-03-08
GB939304701A GB9304701D0 (en) 1993-03-08 1993-03-08 New use
GB9320882.5 1993-10-11
GB939320882A GB9320882D0 (en) 1993-10-11 1993-10-11 New use

Publications (1)

Publication Number Publication Date
CN1118990A true CN1118990A (zh) 1996-03-20

Family

ID=26302552

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94191403A Pending CN1118990A (zh) 1993-03-08 1994-02-16 治疗或预防脑血管疾病药物

Country Status (10)

Country Link
US (3) US5607938A (enExample)
EP (1) EP0688216A1 (enExample)
JP (1) JPH08507514A (enExample)
KR (1) KR960700711A (enExample)
CN (1) CN1118990A (enExample)
AU (1) AU683447B2 (enExample)
CA (1) CA2157671A1 (enExample)
HU (1) HUT68293A (enExample)
TW (1) TW305760B (enExample)
WO (1) WO1994020102A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103755708A (zh) * 2013-12-31 2014-04-30 浙江大学 一种吲哚或吡咯并嘧啶衍生物的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2896811B2 (ja) * 1994-08-16 1999-05-31 ベロイト・テクノロジーズ・インコーポレイテッド セルフローディング式たわみ制御ロール
ATE212860T1 (de) * 1994-09-19 2002-02-15 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US7592344B2 (en) * 2005-11-30 2009-09-22 Solvay Pharmaceuticals Gmbh NK1 and NK2-antagonists and compositions and methods of using the same
RU2340342C2 (ru) * 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU193592B (en) * 1984-01-25 1987-11-30 Glaxo Group Ltd Process for producing tetrahydro-carbazolone derivatives
EP0191562B1 (en) * 1985-01-23 1991-07-10 Glaxo Group Limited Tetrahydrocarbazolone derivatives
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
DE3752062T2 (de) * 1986-12-17 1997-09-11 Glaxo Group Ltd Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
US5244909A (en) * 1986-12-17 1993-09-14 Glaxo Group Limited Methods for the treatment of cognitive disorders
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
DK662687A (da) * 1986-12-17 1988-06-18 Glaxo Group Ltd Anvendelse af tricycliske carbazoloner
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US5173493A (en) * 1988-09-27 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Pyridoindole derivatives and processes for preparation thereof
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
ATE137501T1 (de) * 1989-07-03 1996-05-15 Yoshitomi Pharmaceutical Benzazin-verbindungen und deren pharmazeutische verwendungen
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
US5098889A (en) * 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103755708A (zh) * 2013-12-31 2014-04-30 浙江大学 一种吲哚或吡咯并嘧啶衍生物的制备方法
CN103755708B (zh) * 2013-12-31 2016-09-07 浙江大学 一种吲哚或吡咯并嘧啶衍生物的制备方法

Also Published As

Publication number Publication date
US5866598A (en) 1999-02-02
HUT68293A (en) 1995-06-28
US5698561A (en) 1997-12-16
TW305760B (enExample) 1997-05-21
EP0688216A1 (en) 1995-12-27
AU6045594A (en) 1994-09-26
WO1994020102A3 (en) 1994-10-27
JPH08507514A (ja) 1996-08-13
WO1994020102A2 (en) 1994-09-15
US5607938A (en) 1997-03-04
AU683447B2 (en) 1997-11-13
CA2157671A1 (en) 1994-09-15
HU9402578D0 (en) 1994-11-28
KR960700711A (ko) 1996-02-24

Similar Documents

Publication Publication Date Title
KR0148589B1 (ko) 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트
JP4727925B2 (ja) 統合失調症およびうつ病等の疾患を処置するためのフェノキシピペリジン
CN1292694A (zh) 新用途
BR112021006033A2 (pt) Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina
JP2005514457A5 (enExample)
TWI824259B (zh) Rip1k抑制劑
CN1387530A (zh) 用作磷酸二酯酶vii抑制剂的咪唑并吡啶衍生物
PT90363B (pt) Metodo para o tratamento de doencas auto-imunes em mamiferos utilizando como agentes imunosupressores acidos 4-quinolinocarboxilicos e seus derivados
JP7662528B2 (ja) 複素環式タンパク質キナーゼ阻害剤を含む製剤
EP2124930B1 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
HU197842B (en) Process for producing pharmaceutical compositions comprising 2-alkoxy-n-(1-azabicyclo/2.2.2/oct-3-yl)-benzamide derivatives
CN1118990A (zh) 治疗或预防脑血管疾病药物
SK22004A3 (sk) Farmaceutická kompozícia na moduláciu cholínergnej funkcie a použitie kombinácie NRPA zlúčeniny a antiemetického/antinauzeózneho činidla na výrobu liečiva
CN1077790C (zh) 青光眼治疗剂及眼压降低剂
JPH08511008A (ja) 複素環式化学
RU2002107421A (ru) Алкоксизамещенные бензимидазольные соединения, содержащие их фармацевтические препараты и способы их применения
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
CN1235546A (zh) 肌肉组织变性的预防或治疗剂
KR910016331A (ko) 허혈성 질환 치료제
JP3091518B2 (ja) 骨粗鬆症予防治療剤
JP4598674B2 (ja) 統合失調症治療剤
CN1533292A (zh) 抑制钠/钙交换系统的药剂
JPS6241500B2 (enExample)
JPS645597B2 (enExample)
EP1464644A1 (en) Ergoline derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication